fbpx

Male, 76 y/o

Patient internal ID: 664598388

ICD-10 code

C61 Malignant Neoplasm of Prostate

Diagnosis (incl metastases/stage) and year

September 2010
Metastatic Adenocarcinoma Prostate Cancer, according to Gleason score: 4+4=8. Disease progression in December 2019 cT3a + b N0 M1b, extensive Osteosclerotic Skeletal Metastases.

Previous treatment

Radioligand Therapy (RLT).

Prognosis and survival expectation

The prognosis remains poor, patients with Advanced Prostate Cancer have a 5-year survival rate of close to 30%. The median survival is ~42 months from diagnosis.

Treatment provided

Autologous DCV and CIK (3 doses) over a period of 2 months.

Patient survival/condition and year

The patient has survived for 3 years since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Radioligand Therapy, has benefited in disease stabilisation. More conclusions will be made later.

Date of Review

24/12/2023